|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zakaria S, Donohue JH, Que FG, Farnell MB,
Schleck CD, Ilstrup DM and Nagorney DM: Hepatic resection for
colorectal metastases: Value for risk scoring systems? Ann Surg.
246:183–191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nautiyal J, Kanwar SS, Yu Y and Majumdar
AP: Combination of dasatinib and curcumin eliminates
chemo-resistant colon cancer cells. J Mol Signal. 6:72011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Deep G and Agarwal R: Targeting tumor
microenvironment with silibinin: Promise and potential for a
translational cancer chemopreventive strategy. Curr Cancer Drug
Targets. 13:486–499. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Junttila MR and de Sauvage FJ: Influence
of tumour micro-environment heterogeneity on therapeutic response.
Nature. 501:346–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pickup M, Novitskiy S and Moses HL: The
roles of TGFβ in the tumour microenvironment. Nat Rev Cancer.
13:788–799. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Asiedu MK, Ingle JN, Behrens MD, Radisky
DC and Knutson KL: TGFbeta/TNF(alpha)-mediated
epithelial-mesenchymal transition generates breast cancer stem
cells with a claudin-low phenotype. Cancer Res. 71:4707–4719. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fan QM, Jing YY, Yu GF, Kou XR, Ye F, Gao
L, Li R, Zhao QD, Yang Y, Lu ZH and Wei LX: Tumor-associated
macrophages promote cancer stem cell-like properties via
transforming growth factor-beta1-induced epithelial-mesenchymal
transition in hepatocellular carcinoma. Cancer Lett. 352:160–168.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mallini P, Lennard T, Kirby J and Meeson
A: Epithelial-to-mesenchymal transition: What is the impact on
breast cancer stem cells and drug resistance. Cancer Treat Rev.
40:341–348. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamada D, Kobayashi S, Wada H, Kawamoto K,
Marubashi S, Eguchi H, Ishii H, Nagano H, Doki Y and Mori M: Role
of crosstalk between interleukin-6 and transforming growth
factor-beta 1 in epithelial-mesenchymal transition and
chemoresistance in biliary tract cancer. Eur J Cancer.
49:1725–1740. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu Y, Wang Y, Ren X, Tsuyada A, Li A, Liu
LJ and Wang SE: Context-dependent bidirectional regulation of the
MutS homolog 2 by transforming growth factor β contributes to
chemoresistance in breast cancer cells. Mol Cancer Res.
8:1633–1642. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tabe Y, Shi YX, Zeng Z, Jin L, Shikami M,
Hatanaka Y, Miida T, Hsu FJ, Andreeff M and Konopleva M:
TGF-β-neutralizing antibody 1D11 enhances cytarabine-induced
apoptosis in AML cells in the bone marrow microenvironment. PLoS
One. 8:e627852013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang H, Wu H, Zheng J, Yu P, Xu L, Jiang
P, Gao J, Wang H and Zhang Y: Transforming growth factor β1 signal
is crucial for dedifferentiation of cancer cells to cancer stem
cells in osteosarcoma. Stem Cells. 31:433–446. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma S, Qu W, Mao L, Zhu Z, Jia L, Zhao L
and Zheng X: Antitumor effects of oncolytic adenovirus armed with
Drosophila melanogaster deoxyribonucleoside kinase in colorectal
cancer. Oncol Rep. 27:1443–1450. 2012.PubMed/NCBI
|
|
16
|
Massague J: How cells read TGF-beta
signals. Nat Rev Mol Cell Biol. 1:169–178. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lievre A, Samalin E, Mitry E, Assenat E,
Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou
M and Rougier P: Bevacizumab plus FOLFIRI or FOLFOX in
chemotherapy-refractory patients with metastatic colorectal cancer:
A retrospective study. BMC Cancer. 9:3472009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Gramont A, Figer A, Seymour M, Homerin
M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer
G, et al: Leucovorin and fluorouracil with or without oxaliplatin
as first-line treatment in advanced colorectal cancer. J Clin
Oncol. 18:2938–2947. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Seetharam R, Sood A and Goel S:
Oxaliplatin: Pre-clinical perspectives on the mechanisms of action,
response and resistance. Ecancermedicalscience.
3:1532009.PubMed/NCBI
|
|
20
|
Zhu Z, Mao L, Zhao L, Sun Z, Wang Z, Xu H
and Zheng X: Synergistic therapeutic effect in gastric cancer cells
produced by oncolytic adenovirus encoding Drosophila melanogaster
deoxyribonucleoside kinase. Cancer Biol Ther. 11:874–882. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cassidy J, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F and
Saltz L: XELOX vs FOLFOX-4 as first-line therapy for metastatic
colorectal cancer: NO16966 updated results. Br J Cancer. 105:58–64.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rebucci M and Michiels C: Molecular
aspects of cancer cell resistance to chemotherapy. Biochem
Pharmacol. 85:1219–1226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iseri OD, Kars MD, Arpaci F, Atalay C, Pak
I and Gündüz U: Drug resistant MCF-7 cells exhibit
epithelial-mesenchymal transition gene expression pattern. Biomed
Pharmacother. 65:40–45. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Flavell RA, Sanjabi S, Wrzesinski SH and
Licona-Limon P: The polarization of immune cells in the tumour
environment by TGFbeta. Nat Rev Immunol. 10:554–567. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Marchini S, Fruscio R, Clivio L, Beltrame
L, Porcu L, Nerini I Fuso, Cavalieri D, Chiorino G, Cattoretti G,
Mangioni C, et al: Resistance to platinum-based chemotherapy is
associated with epithelial to mesenchymal transition in epithelial
ovarian cancer. Eur J Cancer. 49:520–530. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bierie B and Moses HL: TGF-beta and
cancer. Cytokine Growth Factor Rev. 17:29–40. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Akhurst RJ: TGF beta signaling in health
and disease. Nat Genet. 36:790–792. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wendt MK, Tian M and Schiemann WP:
Deconstructing the mechanisms and consequences of TGF-β-induced EMT
during cancer progression. Cell Tissue Res. 347:85–101. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aaltonen LA, Peltomäki P, Leach FS,
Sistonen P, Pylkkänen L, Mecklin JP, Järvinen H, Powell SM, Jen J,
Hamilton SR, et al: Clues to the pathogenesis of familial
colorectal cancer. Science. 260:812–816. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gnoni A, Russo A, Silvestris N, Maiello E,
Vacca A, Marech I, Numico G, Paradiso A, Lorusso V and Azzariti A:
Pharmacokinetic and metabolism determinants of fluoropyrimidines
and oxaliplatin activity in treatment of colorectal patients. Curr
Drug Metab. 12:918–931. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kashiwagi E, Izumi H, Yasuniwa Y, Baba R,
Doi Y, Kidani A, Arao T, Nishio K, Naito S and Kohno K: Enhanced
expression of nuclear factor I/B in oxaliplatin-resistant human
cancer cell lines. Cancer Sci. 102:382–386. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kieran D, Woods I, Villunger A, Strasser A
and Prehn JH: Deletion of the BH3-only protein puma protects
motoneurons from ER stress-induced apoptosis and delays motoneuron
loss in ALS mice. Proc Natl Acad Sci USA. 104:pp. 20606–20611.
2007; View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Moser C, Lang SA, Kainz S, Gaumann A,
Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK and Stoeltzing
O: Blocking heat shock protein-90 inhibits the invasive properties
and hepatic growth of human colon cancer cells and improves the
efficacy of oxaliplatin in p53-deficient colon cancer tumors in
vivo. Mol Cancer Ther. 6:2868–2878. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xiu P, Dong X, Dong X, Xu Z, Zhu H, Liu F,
Wei Z, Zhai B, Kanwar JR, Jiang H, et al: Secretory clusterin
contributes to oxaliplatin resistance by activating Akt pathway in
hepatocellular carcinoma. Cancer Sci. 104:375–382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gatza CE, Holtzhausen A, Kirkbride KC,
Morton A, Gatza ML, Datto MB and Blobe GC: Type III TGF-β receptor
enhances colon cancer cell migration and anchorage-independent
growth. Neoplasia. 13:758–770. 2011. View Article : Google Scholar : PubMed/NCBI
|
